Cell-derived microparticles and sickle cell disease chronic vasculopathy in sub-Saharan Africa: A multinational study

Abdoul K Dembélé, Claudine Lapoumeroulie, Mor Diaw, Oumarou Tessougue, Lucile Offredo, Dapa A Diallo, Saliou Diop, Jacques Elion, Yves Colin-Aronovicz, Pierre-Louis Tharaux, Xavier Jouven, Marc Romana, Brigitte Ranque, Caroline Le Van Kim, Abdoul K Dembélé, Claudine Lapoumeroulie, Mor Diaw, Oumarou Tessougue, Lucile Offredo, Dapa A Diallo, Saliou Diop, Jacques Elion, Yves Colin-Aronovicz, Pierre-Louis Tharaux, Xavier Jouven, Marc Romana, Brigitte Ranque, Caroline Le Van Kim

Abstract

Although most individuals with sickle cell disease (SCD) live in sub-Saharan Africa, the natural history of the disease on this continent remains largely unknown. Intravascular haemolysis results in activation of circulating blood cells and release of microparticles (MPs) that exert pro-inflammatory effects and contribute to vascular damage. We designed a case-control study nested in the CADRE cohort (Coeur-Artère-DRÉpanocytose, clinical trials.gov identifier NCTO3114137) and based on extreme phenotypes, to analyse blood cell-derived MPs in 232 adult SS patients at steady state in Bamako and Dakar. Thirty-six healthy adult controls matched by age and sex were recruited in Bamako. The MPs concentrations were higher in SS patients compared to AA controls with a predominance of erythrocyte- and reticulocyte-derived MPs. These erythroid-derived MPs were significantly lower in patients with retinopathy (P = 0·022). Reticulocyte-derived MPs were significantly negatively and positively associated with a history of priapism (P = 0·020) and leg ulcers (P = 0·041) respectively. We describe for the first time the comparative patterns of plasma MPs in healthy subjects and patients with SCD living in sub-Saharan Africa and exhibiting various complications. Because our present results show no clear pattern of correlation between erythroid MPs and the classical hyper-haemolytic complications, we hypothesise a weak relevance of the hyper-haemolysis versus hyper-viscous paradigm in Africa.

Trial registration: ClinicalTrials.gov NCT03114137.

Keywords: microparticles; sickle cell anaemia; sub-Saharan Africa; vascular complications.

© 2020 British Society for Haematology and John Wiley & Sons Ltd.

References

REFERENCES

    1. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. New Eng J Med. 2017;376:1561-73.
    1. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178:792-4.
    1. Allali S, Maciel TT, Hermine O, De Montalembert M. Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020;105:273-83.
    1. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37-47.
    1. Dubert M, Elion J, Tolo A, Diallo DA, Diop S, Diagne I, et al. Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa. Blood. 2017;130:2215-23.
    1. Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30:245-56.
    1. Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:263-99.
    1. Romana M, Connes P, Key NS. Microparticles in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:319-29.
    1. Hierso R, Lemonne N, Villaescusa R, Lalanne-Mistrih M-L, Charlot K, Etienne-Julan M, et al. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study. Br J Haematol. 2017;176:805-13.
    1. Ranque B, Menet A, Diop IB, Thiam MM, Diallo D, Diop S, et al. Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study. Lancet Haematol. 2014;1:e64-73.
    1. Ranque B, Menet A, Boutouyrie P, Diop IB, Kingue S, Diarra M, et al. Arterial stiffness impairment in sickle cell disease associated with chronic vascular complications. Circulation. 2016;134:923-33.
    1. Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F, et al. Standardization of pre-analytical variables in plasma microparticle determination: Results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost. 2013;11:1190-3.
    1. Nieuwland R, Berckmans RJ, McGregor S, Böing AN, Romijn FP, Westendorp RG, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930-5.
    1. Poncelet P, Robert S, Bailly N, Garnache-Ottou F, Bouriche T, Devalet B, et al. Tips and tricks for flow cytometry-based analysis and counting of microparticles. Transfus. Apheres. Sci.. 2015;53:110-26.
    1. Gueye Tall F, Martin C, Malick Ndour EH, Déme Ly I, Renoux C, Chillotti L, et al. Genetic Background of the Sickle Cell Disease Pediatric Population of Dakar, Senegal, and Characterization of a Novel Frameshift β-Thalassemia Mutation [HBB: c.265_266del; p.Leu89Glufs*2]. Hemoglobin. 2017;41:89-95.
    1. Garnier Y, Ferdinand S, Garnier M, Cita KC, Hierso R, Claes A, et al. Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties. Blood. 2020;136:247-56.
    1. Hebbel RP, Key NS. Microparticles in sickle cell anaemia: promise and pitfalls. Br J Haematol. 2016;174:16-29.
    1. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102:2678-83.
    1. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127:750-60.
    1. Nébor D, Romana M, Santiago R, Vachiery N, Picot J, Broquere C, et al. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica. 2013;98:862-7.
    1. Olatunya OS, Lanaro C, Longhini AL, Penteado CFF, Fertrin KY, Adekile A, et al. Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients. Ann Hematol. 2019;98:2507-21.
    1. Garnier Y, Ferdinand S, Etienne-Julan M, Elana G, Petras M, Doumdo L, et al. Differences of microparticle patterns between sickle cell anemia and hemoglobin SC patients. PLoS One. 2017;12:e0177397.
    1. Tantawy AA, Adly AA, Ismail EA, Habeeb NM, Farouk A. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. Platelets. 2013;24:605-14.
    1. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98:464-72.
    1. Cauwenberghs S, Feijge MA, Harper AG, Sage SO, Curvers J, Heemskerk JW. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett. 2006;580:5313-20.
    1. Kostova EB, Beuger BM, Klei TRL, Halonen P, Lieftink C, Beijersbergen R, et al. Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Biosci Rep. 2015;35:e00187.
    1. Rank BH, Moyer NL, Hebbel RP. Vesiculation of sickle erythrocytes during thermal stress. Blood. 1988;72:1060-3.
    1. Awojoodu AO, Keegan PM, Lane AR, Zhang Y, Lynch KR, Platt MO, et al. Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD. Blood. 2014;124:1941-50.
    1. Abdalla Elsayed ME, Mura M, Al Dhibi H, Schellini S, Malik R, Kozak I, et al. Sickle cell retinopathy. A focused review. Graefes Arch Clin Exp Ophthalmol. 2019;257:1353-64.
    1. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106:3264-7.
    1. Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia. Br J Haematol. 1969;17:527-33.
    1. Liu C, Zhao W, Christ GJ, Gladwin MT, Kim-Shapiro DB. Nitric oxide scavenging by red cell microparticles. Free Radic Biol Med. 2013;65:1164-73.
    1. Halabi-Tawil M, Lionnet F, Girot R, Bachmeyer C, Lévy PP, Aractingi S. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol. 2008;158:339-44.
    1. Mehari A, Alam S, Tian X, Cuttica MJ, Barnett CF, Miles G, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med. 2013;18:840-7.
    1. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177:536-43.
    1. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365:44-53.
    1. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189:727-40.
    1. Pagnier J, Mears JG, Dunda-Belkhodja O, Schaefer-Rego KE, Beldjord C, Nagel RL, et al. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci USA. 1984;81:1771-3.
    1. Nagel RL, Fabry ME, Pagnier J, Zohoun I, Wajcman H, Baudin V, et al. Hematologically and Genetically Distinct Forms of Sickle Cell Anemia in Africa: The Senegal Type and the Benin Type. N Engl J Med. 1985;312:880-4.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera